Differences in IV alcohol-induced dopamine release in the ventral striatum of social drinkers and nontreatment-seeking alcoholics by Yoder, Karmen K. et al.
Differences in IV alcohol-induced dopamine release in the ventral striatum of social 
drinkers and nontreatment-seeking alcoholics 
Karmen K. Yodera,b,c,d, Daniel S. Albrechta,b,c,1, Mario Dzemidzica,b,e, Marc D. Normandina,2, 
Lauren M. Federicia,b, Tammy Gravesa,f, Christine M. Herringa,b, Karen L. Hilea,b, James W. 
Waltersa,b, Tiebing Liangf, Martin H. Plaweckig, Sean O’Connorg,h, David A. Karekena,b,e,g 
aDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine, R2-
E124, 950 W. Walnut St., Indianapolis, IN, USA (IUSM) 
bCenter for Neuroimaging, IUSM, GH Ste. 4100, 355 W. 16th St., Indianapolis, IN USA 46202 
cStark Neurosciences Research Institute, IUSM, NB Ste. 414, 320 W. 16th St., Indianapolis, IN 
USA 46202 
dDepartment of Psychology, Indiana University – Purdue University at Indianapolis, 402 N. 
Blackford St., Indianapolis, IN USA 46202 
eDepartment of Neurology, IUSM; GH Ste. 4700, 355 W. 16th St., Indianapolis, IN USA 46202 
fDepartment of Medicine, IUSM; 340 W. 10th St., STe. 6200, Indianapolis, IN USA 46202  
gDepartment of Psychiatry, IUSM; GH Ste. 4800, 355 W. 16th St., Indianapolis, IN USA 46202 
hRoudebush Veteran’s Administration Medical Center, 1481 W. 10th St., Indianapolis, IN USA 
46202 
Current address footnotes here:  
1Current address: Martinos Center for Biomedical Imaging, Massachusetts General Hospital, 
Harvard Medical School, 149 Thirteenth Street, Room 2301, Charlestown, MA USA 
02129
2Current address:  Center for Advanced Medical Imaging Sciences, Department of Radiology, 
Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston MA, USA 
02114  
Corresponding Author:  
Karmen K. Yoder, Ph.D. 
Associate Professor of Radiology and Imaging Sciences 
Center for Neuroimaging 
Indiana University School of Medicine 
Goodman Hall Ste 4100, 355 W. 16th St., Indianapolis, IN 46202 
Ph1 317.963.7507; Ph2 317.278.9840; Fax 317.274.1067; kkyoder@iupui.edu 
_________________________________________________________________________________
 
This is the author's manuscript of the article published in final edited form as: 
Yoder, K. K., Albrecht, D. S., Dzemidzic, M., Normandin, M. D., Federici, L. M., Graves, T., … Kareken, D. A. (2016). 
Differences in IV alcohol-induced dopamine release in the ventral striatum of social drinkers and nontreatment-seeking 
alcoholics. Drug and Alcohol Dependence, 160, 163–169. http://doi.org/10.1016/j.drugalcdep.2016.01.001
Abstract 
 
Background:  Striatal dopamine (DA) has been implicated in alcohol use disorders, but it is still 
unclear whether or not alcohol can induce dopamine release in social drinkers.  Furthermore, no 
data exist on dopamine responses to alcohol in dependent drinkers.  We sought to characterize 
the DA responses to alcohol intoxication in moderately large samples of social drinkers (SD) 
and nontreatment-seeking alcoholics (NTS).  Methods:  Twenty-four SD and twenty-one NTS 
received two [11C]raclopride (RAC) PET scans; one at rest, and one during an intravenous  
alcohol infusion, with a prescribed ascent to a target breath alcohol concentration (BrAC), at 
which it was then “clamped.”  The alcohol clamp was started 5 min after scan start, with a linear 
increase in BrAC over 15 min to the target of 80 mg%, the legal threshold for intoxication.  
Target BrAC was maintained for 30 min. Voxel-wise binding potential (BPND) was estimated with 
MRTM2.  Results.  IV EtOH induced significant increases in DA in the right ventral striatum in 
NTS, but not SD.   No decreases in DA were observed in either group.  Conclusions: Alcohol 
intoxication results in distinct anatomic profiles of DA responses in SD and NTS, suggesting that 
in NTS, the striatal DA system may process effects of alcohol intoxication differently than in SD.        
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1. Introduction 
 
There is strong evidence that the neurotransmitter dopamine (DA) plays multiple roles in 
alcoholism and other addictions (Berridge, 2007; Horvitz, 2000; O'Tousa and Grahame, 2014; 
Redgrave et al., 1999; Salamone et al., 2005).  Despite the wealth of preclinical literature, the 
functions of DA in human alcohol use disorders (AUD) remain poorly understood.  Thus, 
determining how striatal DA responds to alcohol continues to be pivotal for developing 
preventative and therapeutic approaches.   
 
Several groups have used positron emission tomography (PET) with the D2/D3 radioligand 
[11C]raclopride (RAC) to study the effects of alcohol ingestion on striatal DA.  Oral alcohol 
appears to cause modest increases in dopamine in the ventral striatum of healthy subjects 
(Boileau et al., 2003; Setiawan et al., 2014; Urban et al., 2010), with more notable effects in 
men (Urban et al., 2010) and in subjects with traits that may increase risk for AUD (Setiawan et 
al., 2014).  However, there are properties of oral alcohol intake that complicate interpretation of 
these studies.  First, the chemosensory (smell, taste) and somatosensory (oral sensations) 
characteristics of alcohol have powerful Pavlovian associations with intoxication.  In rodents, 
these conditioned cues are believed to mediate the acute increases in striatal DA observed in 
oral alcohol self-administration studies (Doyon et al., 2005), we have shown in humans that 
beer flavor provokes DA release in the ventral striatum (Oberlin et al., 2015).  Additionally, even 
with well-controlled dosing, oral ingestion of alcohol results in highly variable rates and 
concentrations of brain alcohol exposure because of inter-subject differences in stomach pH, 
volume of stomach contents, age, gender, and first-pass metabolism (Ramchandani et al., 
2009).  Different brain exposure timecourses, such as those induced by different peak breath 
alcohol concentrations (BrACs) and/or differing rates of BrAC increase, are likely to induce 
variation in the timing and magnitude of DA responses across subjects.  In turn, variability in DA 
release profiles can cause unwanted variance in the outcome measure of RAC binding potential 
(Endres and Carson, 1998; Yoder et al., 2004).   
 
Intravenous (IV) alcohol infusion avoids these potential confounds.  The physiologically-based 
pharmacokinetically (PBPK) model based IV alcohol clamp (O'Connor et al., 2000) precisely 
controls alcohol infusion rates using PBPK model parameters customized for each individual 
(Plawecki et al., 2007).  This permits control over the timing of alcohol delivery, minimizes 
experimental variation in the brain’s exposure to alcohol across subjects, and allows the 
maintenance (“clamping”) of a target breath alcohol concentration (BrAC).  Our initial RAC PET 
studies with the PBPK-IV alcohol clamp did not show alcohol-induced DA release at either 
60mg% or 80mg% (the latter being the legal definition of intoxication) (Yoder et al., 2007; Yoder 
et al., 2005).  However, these were relatively small samples, and there was variable timing of 
initiation of alcohol administration, leading to different brain alcohol exposures across subjects.   
Using similar IV clamping methods, Ramchandani et al. (Ramchandani et al., 2010) found that 
only social drinkers with the minor (and statistically rare) G allele of the functional µ-opioid 
receptor polymorphism (OPRM1 A118G) had measurable IV alcohol-induced DA release.  In 
contrast, there were no apparent effects in subjects homozygous for the major 118A allele.  
More recently, Aalto et al. reported striatal DA release from a bolus IV alcohol infusion in a small 
group of social drinkers (Aalto et al., 2015), although imaging during this non-PBPK paradigm 
may have captured both ascending and descending limbs of brain alcohol exposure.  Taken 
together, the PBPK-IV clamp data seem to suggest that IV alcohol may not produce a robust DA 
response in social drinkers; however, Type II error cannot be ruled out, given the sample sizes 
of all three PBPK-based infusion studies.   
 
Although evidence suggests that alcoholics have functional alteration of the DA system 
(Martinez et al., 2005; Narendran et al., 2014; Volkow et al., 2007), no research has used an 
alcohol challenge to induce DA release in dependent drinkers.  Prior work examined abstinent 
alcoholics during treatment and/or withdrawal, and utilized psychostimulants to probe DA 
function.   
 
Thus, to better understand how the DA system responds to alcohol both in subjects with and 
without alcohol use disorders, we studied nontreatment-seeking alcoholics (NTS, n = 21) and 
social drinkers (SD, n = 24) with a behaviorally relevant stimulus:  alcohol intoxication.  We 
hypothesized that alcohol challenge would result in DA release in both SD and NTS.       
 
   
  
2. Materials and Methods 
2.1. Subjects 
Procedures were approved by the Indiana University Institutional Review Board in accordance 
with the Belmont Report.  Written informed consent was obtained after confirmation that breath 
alcohol concentration (BrAC) was 0 mg% and study procedures were explained.  Twenty-four 
social drinkers (SD) and twenty-one nontreatment-seeking alcoholics (NTS) completed 
procedures with viable datasets.  Subsets of baseline RAC data have been published (Albrecht 
et al., 2013; Yoder et al., 2011a; Yoder et al., 2012).  General inclusion criteria were: men and 
women 21-55 years of age and the ability to read, understand, and complete all procedures in 
English.  Subjects underwent the Semi-Structured Assessment for the Genetics of Alcoholism 
(Bucholz et al., 1994) to confirm the presence or absence of alcohol use disorders (AUD).  NTS 
met DSM-IV criteria for alcohol dependence, had neither received treatment within the past 
year, nor were actively seeking treatment.  Exclusion criteria were:  history or presence of any 
psychiatric, neurological, or other medical disorder and/or current use of psychotropic or other 
medications that could influence study outcome, contraindications for safety during magnetic 
resonance imaging (MRI), positive urine pregnancy test, testing positive for illicit/illegal 
substance use via urine toxicology screen (results were evaluated within context of reported 
use, e.g., recent outpatient surgical procedures).   One NTS subject met criteria for marijuana 
abuse as determined by the Structured Clinical Diagnostic Interview for DSM-IV disorders I 
module for substance use disorders.  Nicotine dependence was permitted.  Inclusion of subjects 
who self-reported occasional marijuana use was determined on a case-by-case basis by the PI 
(KKY).       
 
Other characterization included:  medical history and demographic questionnaires, the 90-day 
Timeline Follow-Back for alcohol use (TLFB, (Sobell et al., 1986)), an adaptation of the TFLB for 
marijuana use,  Alcohol Dependency Scale (ADS; (Skinner and Allen, 1982)),  Fagerstrom 
Smoking Questionnaire (Pomerleau et al., 1994), Edinburgh Handedness Inventory (Oldfield, 
1971), and an internally-developed substance use questionnaire.   
 
2.2.  Intravenous Alcohol Infusion   
Individualized alcohol infusion profiles were precomputed via the PBPK model.  Input 
parameters included age, height, weight, and gender (O'Connor et al., 2000).  Two profiles were 
calculated, such that IV infusions of alcohol (6% vol/vol) would achieve target BrACs of 60 mg% 
(“morning infusion” ~4-6 hours before PET; see below) and 80 mg% (during the second PET 
scan).   
 
The PBPK-modeled IV alcohol procedure results in intoxication similar to that of oral alcohol 
ingestion (Ramchandani et al., 2004).  However, as the infusion itself and the rapid rise of BrAC 
can be novel, and given that novelty can induce DA release (De Leonibus et al., 2006; Rebec et 
al., 1997), we had subjects undergo a brief IV alcohol infusion prior to PET imaging.  Subjects (n 
= 42) received an IV infusion the morning of the PET study  (see 2.3).  A 60 mg% target for the 
morning infusion insured sufficient time (e.g., ~4-6 hours) for BrAC to return to 0 mg% prior to 
baseline PET.  Two SD and 1 NTS received the morning infusion on a separate day (i.e., PET 
was acquired at a later date).   
 
2.3.  Study Day Procedures 
Figure 1 presents a typical study-day timeline.  To prevent unwanted effects of craving or 
abstinence, subjects were not required to remain abstinent from alcohol, nicotine, or caffeine 
prior to the study.  Subjects were not permitted to smoke cigarettes or have caffeinated drinks 
during the study day.  Upon arrival, BrAC measurements were taken to ensure BrAC = 0 mg%.  
An IV catheter was placed in an antecubital vein.  Blood samples were acquired for OPRM1 
genotyping (see Supplementary Materials).  Subjects were given a full breakfast, and then 
underwent an IV alcohol infusion to a target of 60 mg% (see 2.2).  The first 21 subjects to 
participate received a “ramp” to target BrAC over 15 min, and were “clamped” for 30 min.  The 
remaining 24 subjects (14 SD, 10 NTS) received only the 15 min ramp to target of 60 mg% 
(elimination of the clamp permitted scheduling flexibility, as subjects would return to 0 mg% 
more quickly before imaging).  Subjects subsequently received a structural MRI scan, lunch, 
and two RAC scans in the afternoon (see below). After completing the alcohol RAC PET scan, 
subjects were escorted back to the CRC where they remained until BrAC was <20mg%.    
 
To avoid confounds of nicotine withdrawal and/or cigarette craving on D2/D3 receptor availability 
(Brody et al., 2006; Volkow et al., 2006; Wong et al., 2006), transdermal nicotine patches (TNP) 
were placed on cigarette smokers (SD, n = 12; NTS, n = 18) shortly after arrival; dose was 
based on self-report of cigarettes smoked/day.  TNPs effectively minimize craving in cigarette 
smokers during studies of similar length (Yoder et al., 2012).  Test-retest variability of RAC is 
stable in subjects wearing TNP (Yoder et al., 2011a).   
 
Subjective ratings were acquired every 5- 10 min during the morning infusion and both RAC 
scans.  Questions were presented on a computer monitor; subjects responded along a visual 
analog scale (VAS) with a mouse.  Items included four questions “How high (intoxicated, 
stimulated, sedated) do you feel right now?” that were anchored by 0 (“not at all”) and 100 (“the 
most ever”).  Area under the curve (AUC) was calculated with the trapezoidal rule for VAS data 
collected during PET.    
 
2.4.  Imaging 
An MP-RAGE structural MRI was acquired in a Siemens 3T Magnetom Trio-Tim (Siemens, 
Erlangen, Germany).  
 
Subjects received two [11C]raclopride (RAC) scans in the afternoon:  a resting baseline 
acquisition, followed ~2 hours later by a scan with an IV alcohol infusion (EtOH; Figure 1).  
BrAC in all subjects was 0 mg% prior to baseline scanning.  RAC synthesis was completed as 
described previously (Fei et al., 2004).  RAC PET scans were acquired in a Siemens EXACT 
HR+ (3D mode; septa retracted). A 10-min transmission scan was obtained for attenuation 
correction.   PET scans were initiated with the IV infusion of 514 ± 56 MBq RAC over 1.5 min, 
with dynamic acquisition for 50 min.  IV EtOH began 5 min after the second scan start.  BrAC 
was raised to the 80mg% target over 15 min, and was maintained there for 30 min.   
 
PET scans were acquired on the same day to minimize within-subject variance and subject 
attrition; therefore, a fixed scan order was needed to preclude residual effects of alcohol on a 
subsequent baseline scan.  This invariant order is similar to the bolus-infusion method in PET 
studies, in which baseline is established prior to tracer displacement with a drug.  A resting 
baseline was chosen over a placebo infusion, as placebo conditions can also increase striatal 
dopamine (de la Fuente-Fernandez et al., 2001; Kaasinen et al., 2004), which could result in 
underestimation of any bona fide increase in DA levels, or overestimation of decreases in DA 
(Yoder et al., 2011b).  Similarly, to minimize effects of uncertainty on baseline RAC (Yoder et 
al., 2008), subjects were made explicitly aware of what would happen during each scan.  With 
this design, subjects are thus closer to a behavioral state that would exist during naturalistic 
drinking.  
 
2.5.  Image Processing 
Image processing is similar to that described previously (Yoder et al., 2012).  Briefly, using 
SPM5 (http://www.fil.ion.ucl.ac.uk/spm/), dynamic PET data were co-registered to the MP-
RAGE and spatially normalized to Montreal Neurological Institute (MNI) space via the 
transformation matrix obtained for the structural MRI volume.  Final voxel size was isotropic 2 
mm/side. 
 
Cerebellar regions of interest (ROIs) were created for each subject, and time-activity curves for 
this ROI were generated with the MarsBaR toolbox (http://marsbar.sourceforge.net/).    
 
2.6.  Parametric Image Generation and Analysis 
D2/D3 receptor availability was indexed with BPND, the binding potential of [11C]raclopride (Innis 
et al., 2007)). Voxel-wise BPND estimates were obtained with the multilinear reference tissue 
method with a common reference region efflux rate to facilitate robust performance on noisy 
voxel data (Ichise et al., 2003).  Parametric BPND images were smoothed with an isotropic 4mm 
Full Width at Half Maximum Gaussian kernel.  In three subjects, there was uncorrectable head 
motion near the end of scanning, so either 30 min (2 SD) or 45 min (1 NTS) of data were utilized 
to generate the BPND images for both scan conditions. This does not result in major decrements 
in BPND values, and does not corrupt the validity of the within-subject analysis approach (Yoder 
et al., 2009).  
 
Smoothed parametric images were entered into a 2 scan (rest, IV alcohol) x group (SD, NTS) 
full factorial model in SPM5.  Model contrasts tested for main effects of alcohol (p < 0.005, 
uncorrected, cluster extent threshold k = 20).  Within the SPM models, the search area was 
restricted to a bilateral binary striatal mask created by averaging a subset of SD and NTS 
resting scan parametric images, including all voxels with BPND values > 0.5.  Functional clusters 
from the main effect contrast were defined as ROIs; average BPND from both scans were 
extracted using MarsBaR.  Change in RAC availability was calculated as [∆BPND = ((BPND-rest-
BPND-alcohol)/BPND-rest)*100%]. One-sample t-tests determined whether extracted ∆BPND values 
were different from zero.    
  
2.7.  Other Statistical Analyses  
Chi-squared and independent t-tests were utilized for categorical and continuous variables, 
respectively.  One-way ANOVA tested for differences in RAC parameters, with Group, Scan, 
and Group*Scan as factors.  Repeated-measures, two-way ANOVA was used to determine 
effects of Time, Group, and Time*Group on subjective ratings.  Correlations were tested with 
Pearson’s correlation.  Significance was set at p < 0.05 (two-tailed).  Data are mean ± s.d. 
unless otherwise specified.   
 
3.  Results 
3.1.  Subjects  
Subject characteristics are presented in Table 1.    
 
3.2.  [11C]Raclopride Parameters 
Radioactivity and mass dose injected are presented in Table 2.  There were no significant 
effects of Group, Scan, or Group*Scan on either parameter.   
 
3.3.  Breath Alcohol Concentration 
Table 3 presents the post-infusion BrAC measurements for both the “morning infusion” and the 
RAC scan infusion.  There were no significant group differences for either measurement.   
 
3.4.  Subjective Responses to IV Alcohol during RAC PET 
Figure 2 illustrates the time course of subjective ratings of “High” for SD and NTS during the 
alcohol RAC scan.  The time course of the subjective perceptions followed the timing of the IV 
alcohol infusion (see also 2.4).  There was a significant effect of Time, but no effect of Group or 
Time*Group.  Least significant difference post-hoc testing revealed that ratings at t = 5, 10, 15, 
and 20 minutes were different from all other time points (p < 0.02).  Ratings at t = 30, 40, and 50 
min were not different from one another.  Effects were similar for “Intoxicated”, “Sedated”, and 
“Stimulated,” (data not shown); these four ratings are highly intercorrelated (data not shown).   
 
3.5.  Dopamine Responses to IV Alcohol  
Figure 3 shows the main effects of alcohol ([BPND- BL > BPND-EtOH]; indicative of increases in 
dopamine; p < 0.005, uncorrected; k = 20).  Across all subjects, alcohol increased DA in the 
right ventral striatum (VST, cluster size k = 48; peak voxel at [10 6 -10], Z = 3.56, punc < 0.0001) 
and in the right piriform cortex (cluster size k = 63; peak voxel [30 6 -16]; Z = 3.87, punc < 
0.0001).  The extracted ∆BPND values for each cluster are listed in Table 4.   
 
In the right VST cluster, ∆BPND was significantly different from zero in NTS, but not SD.  SD had 
a significant increase in DA in a region approximating the right piriform area.     
 
Alcohol did not result in any decreases in striatal DA in either SD or NTS.   
 
The results remained significant without the NTS subject with comorbid marijuana abuse (data 
not shown).  This subject’s ∆BPND value from the VST cluster was within 1 standard deviation of 
the group mean; ∆BPND from the piriform region was within 2 s.d. of the group mean.   
 
3.6.  DA Responses and Subjective Ratings 
Extracted BPND data from the right VST and piriform area clusters were assessed for 
relationships with subjective rating AUC. There were no correlations between BPND in either 
region and AUC for subjective ratings of “High”, “Intoxicated”, “Sedated”, and “Stimulated.”   
When groups were tested separately, there were no correlations between subjective ratings and 
BPND in NTS.  In SD, there were modest correlations between BPND and “High” and “Intoxicated” 
(r = 0.36 and 0.31, respectively, p < 0.05).  However, visual analysis of the plot revealed that the 
significance was likely driven by outliers (data not shown).   
 
3.7.  OPRM1 A118G Polymorphism 
As the OPRM1 A118G polymorphism may modulate the DA response to IV alcohol 
(Ramchandani et al., 2010), we verified this genotype in our subjects (Table 1; for methods, see 
Supplementary Material). Genotyping data were unavailable for 2 SD and 2 NTS.  The low 
sample frequency of the G allele precluded analyses by genotype.     
 
  
4.  Discussion 
 
This study examined the effect of alcohol intoxication on striatal DA responses in moderately 
large samples of SD and NTS.  IV alcohol infusion with PBPK modeling (O'Connor et al., 2000; 
Ramchandani et al., 1999) was employed to precisely control the timing of brain alcohol 
exposure across all subjects, and to avoid the confound of conditioned chemosensory cues on 
VST DA (Doyon et al., 2003; Oberlin et al., 2013).  The primary finding was that SD and NTS 
subjects exhibited different magnitudes of VST DA release to an IV alcohol infusion targeted to 
a BrAC of 80mg%.  Specifically, NTS subjects had statistically significant increases in DA in 
right ventral striatum, whereas SD did not.  No decreases in DA were observed in either group.  
To our knowledge, this is the first study to report the effects of alcohol intoxication on the striatal 
DA system in dependent, current drinkers.   
 
Even with a large sample, and uniformity in timing and character of brain alcohol exposure, we 
did not find that intravenously administered alcohol induced significant changes in VST DA in 
social drinkers.  The only other published PBPK-modeled IV alcohol infusion protocol to 
examine DA release with PET was Ramchandani et al. (2010); our social-drinking sample most 
closely corresponds to their OPRM1 118AA group.  There was no apparent effect on IV alcohol 
on VST DA in the Ramchandani et al. 118AA sample, which is consistent with data in the 
present study.  Aalto et al. (2015) reported alcohol-induced DA release in 9 social drinkers using 
a bolus-infusion RAC PET protocol.  The bolus-infusion approach, as in our design, measures 
baseline and challenge conditions successively within the same session, and thus avoids 
between-day variance.  However, some other features may not make their study a good 
comparison to the present work.  The ethanol concentration they used was above 6.0% v/v 
(7.6%), which, in our experience, can cause significant endothelial irritation.  Additionally, their 
range of ethanol exposure was quite large (90-160 mg%), and the non-PBPK infusion is likely to 
have included both the rising and descending limbs of the BrAC curve.  Finally, subjects in the 
Aalto study were naïve to the alcohol infusion experience, increasing the likelihood of novelty 
effects on DA release (De Leonibus et al., 2006; Rebec et al., 1997).   
 
The observed increase in DA levels in the ventral striatum of NTS with IV alcohol infusion may 
seem intuitively obvious, given the VST’s oft-cited role in “reward”.  However, we did not 
observe any IV alcohol-induced DA release in the SD subjects, who presumably drink alcohol 
on occasion for its reinforcing properties.  This discrepant result raises two interesting points.  
First, it suggests that the VST may be sensitized in alcoholics.  Given that the VST codes for 
stimulus valence (Bischoff-Grethe et al., 2009; Mattfeld et al., 2011; Seymour et al., 2007), an 
attractive interpretation is that IV alcohol intoxication has higher reinforcement value in NTS 
than in SD.   Second, several studies have found that abstinent/detoxified alcoholics have lower 
psychostimulant-induced increases in DA compared to healthy controls (Martinez et al., 2005; 
Narendran et al., 2014; Volkow et al., 2007), which is typically taken as evidence for a 
hypofunctional DA system in chronic alcoholism.  However, this phenomenon may be unique to 
stimulants such as methylphenidate and amphetamine, which have direct and powerful effects 
on dopamine concentration at the levels of the nerve terminal and synapse.  Indeed, 
Spreckelmeyer et al. (Spreckelmeyer et al., 2011) found that opioids, which elicit a very modest 
effect on DA release, did not induce measurable differences in opioid-induced DA release 
between detoxified alcoholics and controls. This, coupled with our present data, indicate 
psychostimulants may not be an appropriate proxy for characterizing the nature of dopaminergic 
function in alcoholism.  The contextually relevant stimulus of alcohol intoxication may constitute 
a better tool for understanding how the DA system functions in the development and 
maintenance of AUD.            
 
It is not clear how to interpret the IV alcohol-induced increase in DA in the piriform cortex in SD.   
The signal-to-noise properties of RAC make it unsuitable for hypothesis testing in regions with 
modest levels of D2/D3 receptors (i.e., outside the striatum).  Although this region was 
apparently included in our mask (2.6), the result was unexpected.  Of note, there was large 
variance in BPND in this region (Table 4).   
 
Although this is a relatively large PET study, it still may be underpowered in SD because of the 
presumably smaller effect size.  Thus, the data could contain type II errors in the VST of the SD 
sample.  However, it is worth noting the results are consistent with our prior work (Yoder et al., 
2005) and results from Ramchandani et al. (2010) in SD with the most common OPRM1 
genotype.  Another limitation is that we cannot distinguish between a predisposing difference in 
VST DA function and long-term effects of chronic drinking, a problem common to all 
neuroimaging studies of addiction.  The prospective longitudinal studies required to answer this 
question are not possible, as research radiotracers cannot be administered to minors.  Finally, 
this study did not employ a placebo condition as a baseline comparator.  As noted (see 2.4), 
placebos can induce DA release, and the uncertainty of subject expectations that may 
accompany placebo designs can confound baseline RAC BP.  We thus opted to implement a 
resting baseline and expected alcohol paradigm, the latter of which more closely models 
expectations during naturalistic drinking.   
 
5. Conclusions 
We used a PBPK-modeled IV alcohol clamp technique to examine the effects of alcohol 
intoxication on striatal DA release in SD and NTS.  We observed increases in right VST DA in 
NTS, but not SD.  To our knowledge, this is the first report of the effects of alcohol on DA in 
currently drinking alcohol-dependent subjects.  The results suggest that the DA system may 
process alcohol intoxication differently in NTS than in SD.  The data may reflect relative group 
differences in perceived valence, reinforcement, or expectancies related to alcohol intoxication, 
hypotheses that require further investigation.     
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Figure Legends 
 
Figure 1.  Typical study day timeline.  RAC, [11C]raclopride PET scan; ICRC; Indiana Clinical 
Research Center.    
 
Figure 2.  Subjective ratings for “high” during the alcohol RAC PET scan.  Left y-axis, visual 
analog ratings for “high” for SD (filled circles, black line) and NTS (open circles, dotted line). 
Data are mean ± s.d.  Data were not available for one NTS subject.  Alcohol infusion was 
started 5 minutes after the RAC injection (t = 0; gray arrow).  The BrAC target for the 30 minute 
IV alcohol clamp (gray bar) was 80 mg%.    See text for details.   
 
Figure 3.  Voxel-wise results for main effect of alcohol across all subjects, indicating where IV 
ethanol increased dopamine relative to the resting baseline [BPND-rest > BPND-alcohol].  See text for 
details.  Display height, p < 0.005, uncorrected; cluster extent threshold k = 20 voxels. Color bar 
indicates the t-statistic.  See text for details.  The magnitudes of ∆BPND from each cluster, by 
group, are presented in Table 4.    
 
 
 
 
 
 
 
 
 
  
Table 1.  Subject demographics and characteristics.   
 SD NTS p 
N 24 21 n.s. 
Age 33.9 ± 8.5 36.6  ± 8.5 n.s. 
gender 6F 3F n.s. 
race 8AA 10AA n.s. 
ethnicity 1HL 0HL N/A 
education (years) 14.1 ± 2.3 12.9 ± 1.5 < 0.05 
handedness 24R 20R, 1A N/A 
OPRM1 A118G* 
118AA: 16 
118AG: 5 
118GG: 1 
118AA:  17 
118AG: 2 
118GG:  0 
 
drinks/dd 2.9 ± 1.3 9.1 ± 3.0 < 1x10-10 
drinks/week 4.4 ± 3.1 40.6 ± 20.3 < 1x10-10 
ADS 4.0 ± 2.9 12.9 ± 6.2 < 1x10-06 
cigarette smokers 12 18 < 0.02 
Fagerstrom (smokers only) 3.85 ± 1.46 3.78 ± 2.18 n.s. 
 
AA = African American, HL = Hispanic Latino, R = Right handed, A = Ambidextrous.   
*Genotyping data available for 22 SD and 19 NTS. 
 
Table 2.  [11C]raclopride injection parameters by group and scan.  
 
 SD NTS 
MBq   
Rest 529 ± 55.5 503 ± 59.2 
EtOH 522 ± 51.8 507 ± 59.2 
   
nmol/kg   
Rest 0.13 ± 0.06 0.15 ± 0.07 
EtOH 0.12 ± 0.05 0.13 ± 0.05 
 
 
 
 
  
Table 3.  Post-infusion breath alcohol concentrations (BrAC).   
 SD NTS p 
Morning infusion 
(target:  60 mg%) 59.9 ± 10.1 56.0 ± 9.0 n.s. 
PET infusion (target:  
80 mg%) 72.7 ± 9.7 69.9 ± 9.8 n.s. 
 
 
  
Table 4.  ∆BPND values for the clusters extracted from the main effects of alcohol contrast.   
 
 SD  NTS 
 BPND-rest BPND-alcohol ∆BPND  BPND-rest BPND-alcohol ∆BPND 
Right Ventral 
Striatum 1.42 ± 0.17 1.34 ± 0.21 5.2 ± 13.0  1.47 ±  0.20 1.33 ± 0.25 9.0 ± 13.6† 
Right Piriform 
Cortex 0.73 ± 0.21 0.62 ± 0.22 13.9 ± 19.2‡  0.74 ±  0.31 0.65 ± 0.17 4.5 ± 30.6 
 
†significantly different from zero, p = 0.006 
‡significantly different from zero, p = 0.002 
 
 
 
 
 
Supplementary Materials 
Genotyping for OPRM A118G polymorphism  
Genotyping for the OPRM A118G polymorphism was conducted in order to determine whether 
RAC PET data could be analyzed with respect to presence or absence of the 118G allele.  
Blood samples were analyzed at the NIAAA-funded Indiana University Alcohol Research 
Center.  DNA was isolated using the “HotSHOT” method, which is a fast and cost-effective way 
to isolate PCR quality genomic DNA (Truett et al., 2000). In this method, TaqMan probes are 
used for allelic discrimination (Applied BioSystems, Foster City, CA). The allelic discrimination 
assay is a multiplexed (one primer pair/ two probes per reaction), end-point (data is collected at 
the end of the PCR process) assay. Each assay mix contains two different TaqMan probes, 
labeled with VIC or FAM fluorescent reporter dye, which bind preferentially to one of the alleles. 
The genotype of each sample is determined by the fluorescence levels of the reporter dyes and 
is clustered on a graph with other samples of the same genotype. Each reaction contains 5 ul of 
2X TaqMan Universal PCR Mastermix, No AmpErase UNG, 3.75 ul of water, 0.25ul of 40X 
Assay Mix, and 1ul of DNA sample. Eight or eleven controls are included on each 96-well plate: 
2 no template controls, 2 or 3 heterozygous samples and 2 or 3 of each of the homozygous 
samples. Since genotyping is done by endpoint reading, the thermocycling is carried out in MJ 
Research PTC-200 thermocyclers. The PCR products are then analyzed in an ABI PRISM® 
7300 Sequence Detection System (SDS) instrument. SDS Software 1.3.1 converts the raw data 
to pure dye components and plots the results of the allelic discrimination on a scatter plot of 
Allele X versus Allele Y; each genotype appears on the graph as a cluster of points. 
 
 
 
Truett, G.E., Heeger, P., Mynatt, R.L., Truett, A.A., Walker, J.A., Warman, M.L., 2000. 
Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris 
(HotSHOT). BioTechniques 29, 52, 54. 
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